US, Japan reaffirm FX commitments; Kato cites significance after US tariff order

The US and Japan finance ministers reaffirmed their G7 commitments on currency policy, stressing exchange rates should remain market-driven, with intervention limited to disorderly markets and operations disclosed monthly. Japan’s Finance Minister Kato said the joint statement was especially significant in light of the new US tariff order, while noting there were no talks with Treasury Secretary Bessent on…

Read more

Lagarde speech: Disinflationary process is over

Christine Lagarde, President of the European Central Bank (ECB), explains the ECB’s decision to leave key rates unchanged at the September policy meeting and responds to questions from the press. Join our ECB Live Coverage here Key quotes “Disinflationary process is over.” “We are still in a good place.” “Inflation is where we want it to be.” “Domestic economy…

Read more

Technical Analysis of US Crude, XAUUSD, and EURUSD for Today (September 11, 2025)

2025.09.11 2025.09.11 Short-Term Analysis for Oil, Gold, and EURUSD for 11.09.2025 Alex Rodiоnovhttps://www.litefinance.org/blog/authors/alex-rodionov/ I welcome my fellow traders! I have made a price forecast for the USCrude, XAUUSD, and EURUSD using a combination of margin zones methodology and technical analysis. Based on the market analysis, I suggest entry signals for intraday traders. Oil is trading in an upward correction….

Read more

Lagarde speech: Trade uncertainty has diminished

Christine Lagarde, President of the European Central Bank (ECB), explains the ECB’s decision to leave key rates unchanged at the September policy meeting and responds to questions from the press. Join our ECB Live Coverage here Key quotes “Trade uncertainty has diminished.” “All governments need to operate on basis of EU fiscal framework.” “Minimal deviation from target will not…

Read more

Short-Term Analysis for BTCUSD, XRPUSD, and ETHUSD for 11.09.2025

2025.09.11 2025.09.11 Short-Term Analysis for BTCUSD, XRPUSD, and ETHUSD for 11.09.2025 Roman Oneginhttps://www.litefinance.org/blog/authors/roman-onegin/ Dear readers, I’ve prepared a short-term forecast for Bitcoin, Ripple, and Ethereum based on the Elliott wave analysis. Bitcoin aims to reach a new bullish target. The article covers the following subjects: Major Takeaways BTCUSD: the quotes will likely rise in correction 2 towards 115,952.00. Long…

Read more

Chart Art: Is WTI Crude Oil (USOIL) Going for a Reversal?

WTI crude oil made a couple of failed attempts to break below the $62 per barrel mark, creating a potential double bottom on its 4-hour time frame. Are bulls about to charge soon? WTI Crude Oil (USOIL) 4-hour Chart by TradingView Global supply jitters on resurfacing geopolitical tensions are propping the energy commodity higher these days, as investors are…

Read more

The US treasury auctions off $22 billion of 30 year bonds at a high yield of 4.651%

High risk warning: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all your initial investment; do not invest money that you…

Read more

Lagarde speaks on policy outlook after leaving rates unchanged in September

Christine Lagarde, President of the European Central Bank (ECB), explains the ECB’s decision to leave key rates unchanged at the September policy meeting and responds to questions from the press. Join our ECB Live Coverage here ECB press conference key takeaways “Growth shows resilience of domestic demand.” “GDP data reflects Q1 front-loading.” “Investment should be underpinned by government spending.”…

Read more

Best Pharmaceutical Stocks to Invest in 2025: Top Drug Stocks Analysis

2025.09.11 2025.09.11 Best Pharmaceutical Stocks to Invest: Top Drug Stocks for 2025 Oleg Tkachenkohttps://www.litefinance.org/blog/authors/oleg-tkachenko/ Pharmaceutical stocks are considered high-risk assets. Their performance depends on fundamental factors such as the success of new medicines, the outcomes of pre-launch trials, and competition from both licensed drugs and generics. Although the biotechnology sector may lag behind other industries like technology in the…

Read more